Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2012; 33(02): 205-210
DOI: 10.1055/s-0032-1311801
DOI: 10.1055/s-0032-1311801
Venous Thromboembolism and Arterial Complications
Further Information
Publication History
Publication Date:
30 May 2012 (online)
Abstract
An increasing body of evidence suggests the likelihood of a link between venous and arterial thrombosis. The two vascular complications share several risk factors, such as age, obesity, smoking, diabetes mellitus, blood hypertension, hypertriglyceridemia, and metabolic syndrome. Moreover, there are many examples of conditions accounting for both venous and arterial thrombosis, such as the antiphospholipid antibody syndrome, hyperhomocysteinemia, malignancies, infections, and the use of hormonal treatment. Finally, several recent studies have consistently shown that patients with venous thromboembolism are at a higher risk of arterial thrombotic complications than matched control individuals. We, therefore, speculate the two vascular complications are simultaneously triggered by biological stimuli responsible for activating coagulation and inflammatory pathways in both the arterial and the venous system. Future studies are needed to clarify the nature of this association, to assess its extent, and to evaluate its implications for clinical practice.
-
References
- 1 Singer DE, Albers GW, Dalen JE , et al.; American College of Chest Physicians. Antithrombotic therapy in atrial Fibrillation. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008; 133 (6, Suppl) S546-S592
- 2 Becker RC, Meade TW, Berger PB , et al. American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008; 133: S776-S814
- 3 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329) 71-86
- 4 Hovens MM, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006; 4 (7) 1470-1475
- 5 Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93 (6) 1021-1026
- 6 Tsaloumas MD, Kirwan J, Vinall H , et al. Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye (Lond) 2000; 14 (Pt 6) 821-827
- 7 Prandoni P, Lensing AWA, Cogo A , et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (1) 1-7
- 8 Prandoni P, Villalta S, Bagatella P , et al. The clinical course of deep-vein thrombosis: prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82 (4) 423-428
- 9 Prandoni P, Bilora F, Marchiori A , et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348 (15) 1435-1441
- 10 Hong C, Zhu F, Du D, Pilgram TK, Sicard GA, Bae KT. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005; 183 (1) 169-174
- 11 Eliasson A, Bergqvist D, Björck M, Acosta S, Sternby NH, Ogren M. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost 2006; 4 (9) 1897-1902
- 12 Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117 (1) 93-102
- 13 Borch KH, Braekkan SK, Mathiesen EB , et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study. J Thromb Haemost 2009; 7 (5) 739-745
- 14 Steffen LM, Cushman M, Peacock JM , et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology. J Thromb Haemost 2009; 7 (5) 746-751
- 15 Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010; 121 (17) 1896-1903
- 16 Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjønneland A, Overvad K. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009; 7 (8) 1297-1303
- 17 Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis 2008; 19 (2) 159-165
- 18 Meade TW, Mellows S, Brozovic M , et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2 (8506) 533-537
- 19 Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. ; European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332 (10) 635-641
- 20 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96 (4) 1102-1108
- 21 Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol 2001; 21 (10) 1701-1705
- 22 Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 2006; 8 (2) 100-106
- 23 Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18 (3) 242-248
- 24 Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand 2009; 119 (1) 1-16
- 25 Omine M, Kinoshita T, Nakakuma H, Maciejewski JP, Parker CJ, Socié G. Paroxysmal nocturnal hemoglobinuria. Int J Hematol 2005; 82 (5) 417-421
- 26 Levine RL, LeClerc JR, Bailey JE, Monberg MJ, Sarwat S. Venous and arterial thromboembolism in severe sepsis. Thromb Haemost 2008; 99 (5) 892-898
- 27 Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009; 104 (6) 1445-1451
- 28 Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008; 29 (16) 2031-2041
- 29 Reich LM, Folsom AR, Key NS , et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 2006; 4 (9) 1909-1913
- 30 van der Hagen PB, Folsom AR, Jenny NS , et al. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 2006; 4 (9) 1903-1908
- 31 Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsø study. J Thromb Haemost 2008; 6 (11) 1851-1857
- 32 Quist-Paulsen P, Naess IA, Cannegieter SC , et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 2010; 95 (1) 119-125
- 33 Sørensen HT, Horvath-Puho E, Søgaard KK , et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009; 7 (4) 521-528
- 34 Luxembourg B, Schmitt J, Humpich M , et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: a focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost 2009; 102 (4) 668-675
- 35 Becattini C, Agnelli G, Prandoni P , et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26 (1) 77-83
- 36 Prandoni P, Ghirarduzzi A, Prins MH , et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006; 4 (9) 1891-1896
- 37 Schulman S, Lindmarker P, Holmström M , et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4 (4) 734-742
- 38 Bova C, Marchiori A, Noto A , et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism: a retrospective cohort study. Thromb Haemost 2006; 96 (2) 132-136
- 39 Young L, Ockelford P, Milne D, Rolfe-Vyson V, Mckelvie S, Harper P. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4 (9) 1919-1924
- 40 Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370 (9601) 1773-1779
- 41 Spencer FA, Ginsberg JS, Chong A, Alter DA. The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost 2008; 6 (9) 1507-1513
- 42 Klok FA, Mos IC, Broek L , et al. Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood 2009; 114 (8) 1484-1488
- 43 Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010; 8 (5) 891-897
- 44 Schulman S, Rhedin AS, Lindmarker P , et al; Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332 (25) 1661-1665
- 45 Prandoni P, Lensing AWA, Prins MH , et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137 (12) 955-960
- 46 Migliacci R, Becattini C, Pesavento R , et al. Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica 2007; 92 (6) 812-818
- 47 Mahmoodi BK, Gansevoort RT, Veeger NJ , et al; Prevention of Renal and Vascular End-stage Disease (PREVEND) Study Group. Microalbuminuria and risk of venous thromboembolism. JAMA 2009; 301 (17) 1790-1797
- 48 Steffen LM, Folsom AR, Cushman M, Jacobs Jr DR, Rosamond WD. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Circulation 2007; 115 (2) 188-195
- 49 Glynn RJ, Ridker PM, Goldhaber SZ, Zee RY, Buring JE. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation 2007; 116 (13) 1497-1503
- 50 Pomp ER, Rosendaal FR, Doggen CJ. Alcohol consumption is associated with a decreased risk of venous thrombosis. Thromb Haemost 2008; 99 (1) 59-63
- 51 Lutsey PL, Steffen LM, Virnig BA, Folsom AR. Diet and incident venous thromboembolism: the Iowa Women's Health Study. Am Heart J 2009; 157 (6) 1081-1087
- 52 van Stralen KJ, Le Cessie S, Rosendaal FR, Doggen CJ. Regular sports activities decrease the risk of venous thrombosis. J Thromb Haemost 2007; 5 (11) 2186-2192
- 53 Borch KH, Hansen-Krone I, Braekkan SK , et al. Physical activity and risk of venous thromboembolism: the Tromso study. Haematologica 2010; 95 (12) 2088-2094
- 54 Lindqvist PG, Epstein E, Olsson H. The relationship between lifestyle factors and venous thromboembolism among women: a report from the MISS study. Br J Haematol 2009; 144 (2) 234-240
- 55 Kabrhel C, Varraso R, Goldhaber SZ, Rimm E, Camargo Jr CA. Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ 2011; 343: d3867 epub ahead of print
- 56 Agarwal V, Phung OJ, Tongbram V, Bhardwaj A, Coleman CI. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int J Clin Pract 2010; 64 (10) 1375-1383
- 57 Glynn RJ, Danielson E, Fonseca FA , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360 (18) 1851-1861
- 58 Khemasuwan D, Divietro ML, Tangdhanakanond K, Pomerantz SC, Eiger G. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123 (1) 60-65
- 59 Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost 2006; 4 (9) 1925-1927
- 60 Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases?. J Thromb Haemost 2006; 4 (9) 1886-1890